NCT00394147

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Fox Chase Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.

Detailed description

This research study is being done because we have not yet been able to find the best treatment for recurrent or advanced head and neck cancer (SCCHN). Pemetrexed and gemcitabine have helped fight against SCCHN when each was given by itself. This study is different from others because it tests these two drugs together, which has not been tried before in patients with SCCHN. We will see how well these drugs can work to help to control or shrink your cancer. We also want to find out what effects (good and bad) gemcitabine and pemetrexed have on you and your head and neck cancer. We do not know if these drugs will help you. Your cancer might get better or it might get worse. It might not have any effect on your condition. We can use what we learn from this research study to help other people with the same cancer.

Conditions

• Head and Neck Cancer

Interventions

Type	Name	Description
DRUG	pemetrexed	pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
DRUG	gemcitabine	gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle

Timeline

• Start date: 2006-10-01
• Primary completion: 2008-08-01
• Completion: 2009-12-01
• First posted: 2006-10-31
• Last updated: 2022-08-05
• Results posted: 2022-08-05

Locations

1 site across 1 country: United States